Review of hormone-related issues after cancer immunotherapy
Immune Checkpoint Inhibitor Therapy- Induced Endocrinopathy and Metabolic Diseases -a Case Series of Taiwanese Patients
National Taiwan University Hospital · NCT04079647
This study looks at how cancer immunotherapy may cause hormone and metabolic problems in patients to better understand these side effects and improve future care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 20 Years to 85 Years |
| Sex | All |
| Sponsor | National Taiwan University Hospital (other) |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Taipei) |
| Trial ID | NCT04079647 on ClinicalTrials.gov |
What this trial studies
This study aims to analyze cases of patients who developed endocrinopathy and metabolic diseases following immunotherapy at National Taiwan University Hospital. It will involve a thorough review of patient data, including age, clinical presentation, imaging findings, and treatment responses. By statistically analyzing these cases, the study seeks to enhance understanding of the adverse effects associated with immune checkpoint inhibitors. Additionally, it will compare findings with existing literature to identify patterns and inform future management strategies.
Who should consider this trial
Good fit: Ideal candidates are patients aged 20 and older who have received immunotherapy at NTUH and subsequently developed endocrinopathy.
Not a fit: Patients under 20 years old or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and management of endocrinopathy in patients undergoing immunotherapy.
How similar studies have performed: While there is growing interest in the adverse effects of immunotherapy, this specific focus on endocrinopathy is relatively novel and has not been extensively studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who receive immunotherapy in NTUH and develop endocrinopathy after therapy Exclusion Criteria: * Patients less than 20 years old. Patients who are pregnant
Where this trial is running
Taipei
- Shyang-Rong Shih — Taipei, Taiwan (RECRUITING)
Study contacts
- Study coordinator: Shyang-Rong Shih
- Email: srshih@ntu.edu.tw
- Phone: +886-972653337
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Endocrinopathy